|
|
 |
| |
 |
Management
Team |
 |
|
|
|
John A. Sedor
President and Chief Executive Officer
Mr. Sedor has been our President and Chief Executive Officer since the spin-off from Bentley in 2008. Mr.
Sedor was President of Bentley from 2005 until the spin-off. From 2001 to May 2005, he was President and
CEO of Sandoz, Inc. (a division of Novartis AG). From 1998-2001 Mr. Sedor was President and Chief Executive
Officer at Verion, Inc., a drug delivery company. Previously, Mr. Sedor served as President and Chief
Executive Officer at Centeon, LLC, a joint venture between two major multinational corporations, Rhône-Poulenc
Rorer and Hoechst AG. Previously, Mr. Sedor served as Executive Vice President at Rhône-Poulenc Rorer, Revlon
Health Care and Parke-Davis. Mr. Sedor holds a Bachelor of Science degree in Pharmacy/Chemistry from Duquesne
University, and has studied strategic marketing at both Northwestern University’s Kellogg Graduate School of
Management and Harvard Business School. He has also attended Harvard’s Executive Forum. |
|
|
Lance Berman, M.D.
Senior Vice President and Chief Medical Officer
Dr. Berman has been our Chief Medical Officer since February 2009. Previously, Dr. Berman served at Pfizer from 2003 until 2009. From December 2007 he served as Senior Medical Director and Global Medical Team Leader at Pfizer, responsible for the strategic medical development and evolution of products within the cardiovascular and diabetes portfolio. Previously, Dr. Berman held roles of increasing importance at Schering-Plough from 1999 to 2003 and Janssen Pharmaceuticals (acquired by Johnson & Johnson) from 1996 to 1999. Dr. Berman received his Bachelor of Medicine and Bachelor of Surgery at University of Cape Town in Cape Town, South Africa, and holds a Masters Degree in Pharmaceutical Medicine. |
|
|
Robert P. Hebert
Vice President and Chief Financial Officer
Mr. Hebert has been our Vice President and Chief Financial Officer since the spin-off from Bentley in 2008. From June 2006 until the spin-off, Mr. Hebert was Controller and Principal Accounting Officer for Bentley. In this role, Mr. Hebert managed all of Bentley’s accounting and reporting functions. From May 2003 until June 2006, Mr. Hebert was Bentley’s Director of SEC Reporting & Compliance, Assistant Secretary and Assistant Treasurer. His responsibilities in this role included Bentley’s financial reporting and compliance with the requirements of the Sarbanes-Oxley Act of 2002. Prior to joining Bentley, Mr. Hebert worked as an auditor for Deloitte & Touche LLP from 1995 to 2003. Mr. Hebert received a B.S. in Business Administration with a concentration in accounting from Merrimack College in 1995. |
|
|
Nils Bergenhem, Ph.D.
Vice President and Chief Scientific Officer
Dr. Bergenhem joined CPEX Pharmaceuticals as Chief Scientific Officer in February 2010. Between 2005 and 2010, Dr. Bergenhem held positions as Chief Scientific Officer at Escoublac, Inc., and AdipoGenix, Inc. Previously, Dr. Bergenhem was Vice President for Research at the Institute for Diabetes Discovery between 2002 and 2005, and Director, Diabetes Research at OSI Pharmaceuticals from 2000 to 2002. Dr. Bergenhem held positions of increasing importance at Novo Nordisk from 1996 to 2000. Dr. Bergenhem holds a BS degree in Chemistry from Linkoping University, Sweden, and a Ph.D. in Biochemistry from Umea University, Sweden, and has completed postdoctoral work at University of Michigan, where he also spent three years as Research Investigator. |
|
|
|
|
|
